PARA ONCOLOGY®

GROUND-BREAKING NEW WAY FOR TREATING CANCER – ANY CANCER FOR WHICH THERE IS SUFFICIENT MOLECULAR RESEARCH TO INFORM DR ALEX’S DEVELOPMENT OF AN INDIVIDUAL PROGRAMME

WORKS ALONGSIDE OR AFTER MAINSTREAM OPTIONS

ALSO AIMS TO ENHANCE MAINSTREAM THERAPEUTIC EFFECTS – & COUNTER SIDE-EFFECTS OF MAINSTREAM TREATMENTS – AS AN ADDED BONUS, WHERE POSSIBLE

USES DR ALEX’S PROPRIETARY MULTIPLE-TARGET THERAPY – ADDRESSING UP TO EVERY SINGLE TUMOUR PATHWAY MOST RELEVANT TO YOUR VERY OWN CANCER, AS DETERMINED BY EXTENSIVE MOLECULAR MAPPING
(by Independent Facilities)

WE CAN ADDITIONALLY PROVIDE UNIQUE INDIVIDUAL ONCO-IMMUNOLOGICAL PROGRAMMES ALONGSIDE
(from our prior landmark Cancer R&D – which we have advanced & augmented to capitalize on our recent work, and to integrate the most up-to-the-minute scientific knowledge)

ANNOUNCING A MAJOR STRATEGIC INNOVATION IN THE TREATMENT OF CANCER

DEVELOPED OVER 25 YEARS & ‘COMPLETED’ DURING LOCKDOWN:
Dr Alex has devised a brand new way of treating cancer – any cancer, including childhood cancers and rare cancers, and where existing lines of treatment have so far failed to completely eliminate the cancer.

It’s called PARA ONCOLOGY®.

PARAONCOLOGY is a body of knowledge developed by Dr Alex, featuring vast amounts of precious onco-molecular science that simply never gets used in the normal development of anti-cancer drugs, on account of the limitations of the existing medical paradigm. Paraoncology provides us with the facility to offer UNIQUE INTERVENTIONS WITH THERAPEUTIC INTENT taking an innovative approach, based on a new, progressive strategic rationale.

Using proprietary algorithms, we use ‘triangulated’ molecular, compound and clinical science to simultaneously target many different dimensions of a tumour’s operational dynamics all at once (Dr Alex’s unique Multiple Target Onco-Therapy™, using complexity modelling: a completely different model from the – also valuable and often vital – pharma and biotech).

We can target cancers where you have had relatively basic genetic analysis (for example, during histopathology of an excised cancer or cancer biopsy – usually showing ~5 key oncogenes), by marrying the ‘broad-brush signature’ of your tumour with up-to-the-minute science of what molecular profile is most likely for the Type / Stage of your cancer. However, at its best, Paraoncology enables us to develop individual programmes based *absolutely *specifically and **comprehensively on your very own tumour – using extremely advanced ‘encyclopaedic’ molecular tumour analysis, featuring ‘unlimited’ genetic information. This either analyses tumour tissue, or can be determined from Circulating Tumour Cells (CTCs) via a ‘Liquid Biopsy’ (blood draw).

We know the efficacy for *each *individual we treat – because they can undertake Cancer Tracking with a leading Oncology Genetics Facility which monitors levels and oncogenetic profiles of CTCs using samples obtained sequentially and non-invasively. This monitoring also enables us to flex or modify the Individual’s Programme where a cancer is expressing new or rising levels of key mutations, using their own cancer’s genetics, thereby aiming to get ahead of its capacity to develop treatment resistance or become a ‘runaway’ tumour.

This is absolutely not  intended as an ‘alternative’ to mainstream options, where they exist, because although we can monitor each individual’s progress, we will not know the *overall efficacy of our PARAONCOLOGY PROGRAMMES for many years (and are working with a cancer research charity to progress this). Cancer is an extremely serious and life-threatening disease, and we will not treat people refusing standard mainstream options – this is  adjunctive. Indeed, the very best time to start our interventions is when the tumour burden is at its lowest following mainstream programmes – failing that, the sooner, the better.

Dr Alex has long been a world leader in this field – including as a Keynote Speaker internationally. She is uniquely qualified, with an MD and a PhD in Virology, Immunology, Pathology & Molecular Genetics. She has been involved with cancer services and research for over two decades, including at top UK/London facilities, plus working in direct liaison with Specialist Integrative Oncologists worldwide. Dr Alex also developed PARA ONCO-IMMUNOLOGY™ – the methodology for using *Individual Immunology / Immunogenomics in direct alignment with a specific cancer’s known immunological hallmarks. And she is also, to our best knowledge, the only Physician worldwide to have researched and developed a unique, systematic methodology for utilising PNEI at a level of specialism (ie non-generically) that matches the calibre of neuro-immunological / endo-immunological and psycho-immunological science – deliberately and very specifically modifying the wide context of pathways (including brain to body) which directly impact our onco-immunology.